UTMB Research on Severe Asthma (UROSA) Study



Status:Recruiting
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 65
Updated:4/21/2016
Start Date:March 2009
End Date:March 2017
Contact:William Calhoun, M.D.
Email:wjcalhou@utmb.edu
Phone:409-772-1176

Use our guide to learn which trials are right for you!

To identify and understand biologic aspects of severe asthma compared to subjects with mild
to moderate asthma and subjects without asthma (normal or healthy volunteers).

It has been shown that severe asthma differs from milder asthma in its pathophysiology; in
particular we are interested in examining why patients with severe asthma have disease that
is resistant to corticosteroids. While we will be studying patients with severe asthma, we
also need to study subjects to act as controls. To this end we will recruit subjects into
the following groups: Normal volunteers; Mild asthmatics not taking inhaled corticosteroids;
Mild to moderate asthmatics requiring and using inhaled corticosteroids and Severe
asthmatics.

Subjects between the ages of 18 and 65 will be enrolled in this study. We aim to recruit
enough subjects such that 120 male and female participants (30 in each of the above groups)
will complete the bronchoscopy.

Inclusion Criteria:

- All participants must be in good general health (with exception to asthma). • Normal
controls / healthy volunteers (NC) subjects with no past history of asthma or other
lung disease. To determine this, subjects must have an FEV1 equal to or greater than
80% of predicted value and have a normal FEV1/FVC ratio.

Asthma subjects Eligible asthmatic participants must have a physician diagnosis of asthma
for at least 1 year. Participants must either have historical evidence of reversibility of
FEV1 of at least 12%, or demonstrate such a change during the study visits, or must have
historical evidence of a PC20 for methacholine < 8mg/ml.

- Mild Asthma with no Corticosteroids (MANC) will be defined as control of asthma with
short acting β2-agonists or leukotrine antagonist or both, but not requiring inhaled
corticosteroids.

- Mild to Moderate asthma (MMA) will be defined as control of asthma with an inhaled
corticosteroid (less than or equal to 250 mcg daily inhaled fluticasone equivalent)
in addition to the medications listed in the MANC group or long acting β2-agonists.

- Severe asthma (SA) will be defined according to the ATS criteria for Refractory
Asthma (10)

Exclusion Criteria:

- Exclusion criteria apply for all subjects:

- Current smoker, or former smoker with >10 pack years history or having quit
within the past year

- Asthma exacerbation, requiring a new or increased dose of oral corticosteroids,
within the past 30 days

- Pregnant or lactating female

- Significant/uncontrolled medical condition (uncontrolled diabetes, coronary
artery disease, uncontrolled hypertension)

- Diagnosis of emphysema or other significant pulmonary disease

- If, in the opinion of the PI (WJC) the subject has co-morbid conditions that
make them unsafe to undergo bronchoscopy, subjects will be given the choice to
withdraw from the study or allowed to complete visits 1-3 only.
We found this trial at
2
sites
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: William J. Calhoun, M.D.
Phone: 409-747-5871
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials